This Week in BMC Cancer | GenomeWeb

This Week in BMC Cancer


This week in BMC Cancer, a team of US researchers reports that tetrathiomolybdate, a drug used to treat copper overload disorders, also sensitizes ovarian cancer cells to several anticancer drugs. The researchers explored the combination of TM with several reactive oxygen species-generating drugs like mitomycin C, fenretinide, 5-fluorouracil and doxorubicin in ovarian cancer cells.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Nature this week: genomic analysis of 200 bird species, and more.

The Australian High Court rules that isolated genetic material cannot be patented.

The startup incubator Y Combinator is launching a nonprofit research lab.

Wired's Sarah Zhang writes that the fight over who developed the CRISPR/Cas9 genome editing tool first underscores the history of parallel discoveries in science.